Organisation paid for research Program year 2025 Source: CMS Open Payments

Cancer Specialists, LLC

Neither a doctor nor a teaching hospital

Research payments

$1,054,359

72 payments

Through program year 2025, Cancer Specialists, LLC is reported as receiving $1,054,359 in research payments, across 72 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $37,939 8
2024 Research $108,109 17
2023 Research $270,783 15
2022 Research $163,435 10
2021 Research $174,537 9
2020 Research $157,395 5
2019 Research $142,162 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $768,791 38 payments
  2. Celgene Corporation $212,670 11 payments
  3. Novocure Inc. $59,835 19 payments
  4. AbbVie, Inc. $13,062 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) $186,804 7 payments
  2. Prospective REsearch Assessment in Multiple Myeloma: an OBservationaL Evaluation (PREAMBLE) $156,067 7 payments
  3. A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer $119,250 6 payments
  4. Connect MM- The Multiple Myeloma Disease Registry $116,855 5 payments
  5. Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab $89,109 5 payments
  6. Prospective Research Assessment in Multiple Myeloma an ObservationaL Evaluation PREAMBLE $87,480 1 payment
  7. Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry: The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and tr $49,130 2 payments
  8. EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma $45,085 17 payments
  9. Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices $44,928 3 payments
  10. Lung cancer molecular profiling and clinical outcomes in US oncology community practices $43,337 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record